Hofseth BioCare ASA Expands Manufacturing Capacity
Hofseth BioCare ASA (Oslo:HBC) is poised to significantly enhance its manufacturing capabilities and market presence with a major development in Berkåk, Norway. The company is constructing a new enzymatic hydrolysis plant, made possible through a strategic partnership with Symrise, a renowned global supplier of flavors and functional ingredients.
The Strategic Partnership with Symrise
This collaboration includes financing of EUR 5 million from Symrise, which will bolster HBC’s ambitions in the health sector with clinically validated marine-derived ingredients. This partnership not only enhances HBC's operations but also complements the portfolio of both companies, enabling broader access to innovative health solutions.
Distribution Agreements and Market Access
In addition to the construction of the new plant, HBC has entered into an exclusive distribution agreement for its flagship products, OmeGo®, ProGo®, and NT-II™, targeting four of Symrise’s key global accounts. This agreement is expected to significantly amplify HBC's reach into the Consumer Health and Functional Food categories, establishing a strong foothold in these markets.
Funding and Development Plans
The funds from Symrise's loan will be utilized to transform the existing HBC facility in Berkåk into a premier enzymatic hydrolysis plant, which is projected to triple HBC’s current production levels. This strategic investment positions both companies to collaborate on innovative product development while maximizing Symrise’s extensive market presence to promote HBC’s offerings on a global scale.
Anticipated Timelines for the Project
HBC's Berkåk facility is now fully financed, including a credit facility of NOK 60 million from Sparebank 1 Nordmøre. All necessary permits for the construction of the plant are slated for approval in the near future, with groundbreaking expected to follow shortly thereafter. Initial production is targeted for the second quarter of 2027, setting a clear path for HBC's expansion.
Leadership Insights
Dr. Jean-Yves Parisot, CEO of Symrise AG, remarked on the partnership's significance, stating, "This collaboration underscores HBC's unique capabilities and their commitment to scientific advancement in health sectors. Their rigorous clinical studies highlight their expertise in areas critical to health such as metabolic and immune health. This alignment between our missions enhances our ability to innovate in the health landscape."
Sustainability at the Core of Development
HBC's commitment to sustainability drives its operations. The firm has pioneered a proprietary technology to upcycle salmon offcuts, transforming what would typically be waste into bioactive ingredients that contribute to human health. This initiative not only benefits the environment but also positions HBC as a global leader in marine-sourced nutritional science.
Future Prospects for the Partnership
Jon Olav Ødegård, the CEO of Hofseth BioCare, expressed enthusiasm for the partnership and its potential. According to Ødegård, "Symrise has been instrumental in our journey so far, and with their support, we can significantly enhance our market access and operational scale. As the demand for human health and premium pet nutrition continues to escalate, this partnership is crucial for maintaining our growth trajectory and solidifying our position in the marine nutrition sector."
Contact Information for Investors
For more inquiries, please reach out to:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
Email: joo@hofsethbiocare.no
Frequently Asked Questions
What is the main goal of Hofseth BioCare's partnership with Symrise?
The partnership aims to expand HBC's manufacturing capacity and market presence while enhancing health and nutrition offerings.
What products will HBC distribute through Symrise?
HBC has exclusive distribution for OmeGo®, ProGo®, and NT-II™ targeted at key global accounts.
When is the new plant in Berkåk expected to start production?
Initial production at the new Berkåk plant is anticipated to commence in the second quarter of 2027.
How does HBC contribute to sustainability?
HBC's technology upcycles salmon offcuts into bioactive ingredients, promoting sustainability and reducing waste.
How can investors contact Hofseth BioCare?
Investors can contact Jon Olav Ødegård at +47 936 32 966 or via email at joo@hofsethbiocare.no.
